A Phase 2 interventional study of Lorazepam and Placebo in Anxiety, sponsored by St. Justine's Hospital. Completed at 1 site in Canada. Open to participants aged 9 Years to 18 Years. Per ClinicalTrials.gov, last updated 2018-09-05.
Sponsored by St. Justine's Hospital · Phase 2, Interventional, and Treatment
The purpose of this study is to determine the effect of a single dose of Lorazepam on salivary cortisol in children undergoing digestive endoscopy. To do so, the patients will be randomized in three groups. The first group receives the Lorazepam, the second group receives a placebo and the last group receives no intervention. Each patient will have three saliva samples taken at three different time point on the day of the endoscopy and will be asked to fill out questionnaires on anxiety and overall satisfaction of the procedure.
Background: Pediatric digestive endoscopies (gastroscopy and colonoscopy) are invasive procedures. All endoscopic procedure are conducted in the operating room either under intravenous (IV) sedation or general anesthesia. More than 50% of procedures are performed using IV sedation. The current sedation protocol in the endoscopy suite is a combination of Midazolam (0.1 mg/kg) and Fentanyl (1 microgram/kg) in all children. The children undergoing colonoscopies receive and additional administration of Ketamine (0.5 mg/kg).
In a previous study performed in children 10-18 years undergoing upper and lower endoscopy, the investigators found that despite this regimen, 25% of the children expressed a significantly high level of pain during endoscopy under IV sedation.
Because general anesthesia is not available for all children, it is important to investigate strategies that could help in minimizing the discomfort and pain during the procedure.
Salivary cortisol (sCortisol) has been used in several pediatric studies to determine the level of stress in children prior to various medical procedures. In another study done at our site, the investigators have found sCortisol to be a reliable biomarker of stress for children undergoing digestive endoscopies. Furthermore, the mean baseline sCortisol levels were higher in the group that experienced procedural pain.
Lorazepam is a a rapid onset benzodiazepine that has anxiolytic and sedative properties that has been approved by Health Canada as an adjunct therapy for the relief of excessive anxiety that might be present prior to surgical interventions.
Objective:
The primary objective is to investigate the effect of Lorazepam as compared to placebo on the change of the level of sCortisol between baseline (C1) and immediately before endoscopy (C2) in adolescents undergoing a gastroscopy or a colonoscopy. The investigators think that it might be possible to modulate the stress response with the administration of a benzodiazepine as soon as the children arrives at the hospital. Thus children could have a better experience of the digestive endoscopic procedure (less pain and more comfort).
The secondary outcome measure will be:
(1) the proportion of children experiencing procedural pain, (2) the duration of endoscopic procedures, (3) children satisfaction, (4) physician and nurse satisfaction (5) the total dose of Fentanyl and Ketamine per kilogram body weight delivered during the procedure and (6) the mean change between pre-op and postop cortisol levels between the two groups.
Safety outcomes measures: The following adverse events will be sought before and during the endoscopy: prolonged drowsiness, hypotension, hypertension, desaturation, bradycardia.
Exploratory outcomes: the mean change between pre-op and postop cortisol levels in the Group C (No intervention) compared to Group A and B.
Methods:
In this randomized controlled trial children will be assigned to one of the three following groups (no intervention, placebo and active drug). The investigators will collect salivary samples to measure the levels of sCortisol and investigate their variation between three timepoint ( at arrival at the hospital, right before the procedure and right after the procedure). sCortisol levels will be correlated to a questionnaire evaluating the anxiety level in the patient. The research team will also evaluate the pain experienced during the procedure using the Nurse-Assessed Patient Comfort Score (NAPCOMS): a validated tool for the evaluation of pain in subjects undergoing endoscopies).
St. Justine's Hospital is the lead sponsor of 155 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Patient will receive a single dose of either 0,5mg or 1mg of oral Lorazepam depending on their body weight.
Drug: Lorazepam
Patient will receive a placebo similar in color, form and size.
Other: Placebo
Patient will receive no intervention.
Patient receives one or two tablet of 0,5mg Lorazepam according to body weight
Also known as: Apo-Lorazepam
Patient receive one of two tablet of Placebo according to body weight
Change of sCortisol from baseline to one hour after drug administration
Proportion of children with a decrease of sCortisol of at least 15 points between the group Placebo and the group Lorazepam
Time frame: One hour after drug administration
Procedural pain
Proportion of children experiencing procedural pain
Time frame: during endoscopic procedure
Duration of endoscopic procedure
Duration of endoscopic procedure. The time interval in minutes will be measured between the start and the end of each procedure.
Time frame: Through completion of endoscopy: an average of 2 hours after drug administration
Children Satisfaction
Children satisfaction will be evaluated with a validated Satisfaction questionnaire of children undergoing endoscopy
Time frame: Through study completion, an average of 3 hours
Physician Satisfaction
Physician satisfaction will be evaluated with a validated tool : CLINICIAN SATISFACTION WITH SEDATION INSTRUMENT (CSSI)
Time frame: during the endoscopic procedure
Nurse Satisfaction
Nurse satisfaction will be evaluated with a validated tool : NURSE ASSESSED PATIENT COMFORT SCORE (NAPCOMS)
Time frame: during the endoscopic procedure
Medication needed For sedation
Total dose of Fentanyl and Ketamine per kilogram body weight delivered
Time frame: during the procedure
Change in sCortisol levels between pre-op and post-op
Mean change between pre-op and post-op cortisol levels between the two groups (Lorazepam and Placebo)
Time frame: one hour after the endoscopic procedure
Number of participants with Treatment-related Adverse Events (Safety and Tolerability)
The following adverse events will be sought before and during the endoscopy: prolonged drowsiness, hypotension, hypertension, desaturation, bradycardia.
Time frame: during the procedure
Change in level of sCortisol between pre-op and post-op in the group without any intervention
the mean change between pre-op and post-op cortisol levels in the Group C (No intervention)
Time frame: Through study completion, an average of 3 hours
Plan to share: No
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Justine's Hospital